# A Phase 2 Clinical Study of ABSK061 and ABSK043

Source: https://onco.cc/trials/nct06632262/  
OnCo record `nct06632262` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of ABSK061, CAPOX in non-small-cell lung cancer and small-cell lung cancer, run by Abbisko Therapeutics Co, Ltd, now recruiting.

## Summary

A Phase 2 Clinical Study of ABSK061 and ABSK043 is a phase 2 interventional study registered as NCT06632262 by Abbisko Therapeutics Co, Ltd, with 202 participants planned, started 2024-11-13 and due to reach its primary completion in 2029-11-30. Interventions recorded: ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX. Conditions listed: HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06632262
- Phase: 2
- Setting: An Open-label Phase 2, Multicenter, Open-Label Clinical Study to Evaluate the Safety and Efficacy of ABSK061 and ABSK043 with or Without Chemotherapy in Patients with Metastatic/Unresectable Solid Tumors with FGFR2/3 Alterations
- Sponsor: Abbisko Therapeutics Co, Ltd
- Enrolled: 202

## Sources

- ClinicalTrials.gov NCT06632262: https://clinicaltrials.gov/study/NCT06632262

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [ABSK061](https://onco.cc/drugs/absk061/), [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/)
- companies: [Abbisko Therapeutics](https://onco.cc/companies/abbisko/)

---
JSON: https://onco.cc/api/v1/entities/nct06632262.json